Gene therapy biotech AlveoGene launches with lentiviral platform for respiratory diseases
New company AlveoGene, backed by experts at the UK Respiratory Gene Therapy Consortium (GTC), has made its debut with a lead program for rare respiratory disease alpha-1 antitrypsin deficiency (AATD).
Oxford Science Enterprises created the company together with Harrington Discovery Institute, Old College Capital and six GTC scientists. The UK biotech has an exclusive license to the GTC’s next-generation lentiviral delivery platform, InGenuiTy, except with regard to the CFTR gene, which is mutated in cystic fibrosis. Boehringer Ingelheim has taken the reins on that gene and is working on a CF gene therapy candidate using the tech.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.